FDA Approves Second Alzheimer's Drug, Despite Brain Bleed Concerns - Consumer Health News
The FDA on Friday approved lecanemab, a drug which promises to slow the progress of Alzheimer's disease -- but which has also been linked to the deaths of two patients in clinical trials